Authors: Dakota Gustafson, Priya Mistry, Crizza Ching, Inbar Nardi-Agmon, Christopher Yu, Chun-Po Steve Fan, Christian Houbois, Eitan Amir, Thomas Marwick, Husam Abdel-Qadir, Chris McIntosh, Paaladinesh Thavendiranathan, Jason E Fish
Short Description:Blood biomarkers to predict cancer therapy-related cardiac dysfunction (CTRCD) risk remain limited. The aim of this study was to identify circulating biomarkers associated with CTRCD risk in HER2+ breast cancer patients. Pretreatment endothelial-centric and inflammatory biomarkers outperformed both clinical and CMR measures in predicting CTRCD during chemotherapy.
Interest: angiopoeitin-2, biomarkers; breast cancer; cancer therapy–related cardiac dysfunction; cardio-oncology; endothelium; inflammation; machine learning; microRNA; myeloperoxidase; vascular